Skip to main content

elelyso

Generic: taliglucerase alfa·Brand: Elelyso

elelyso: developed by 2 companies · 1 FDA decision.

elelyso evidence translation

What we can confirm

1 FDA record

What it means

More than one developer is source-backed. Until you choose one, AI stays drug-only and does not guess ownership.

What to watch

Watch for new trials or company disclosures after the FDA record.
BioSniper AIPage evidence connected

Prepared research question

What is verified about elelyso, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence1 indications · 0 study sponsors

Related indications

Gaucher disease

Study sponsors

No additional listed-company sponsor is linked.

Development Pipeline (3)
CompanyPhase
PFIZER INC (PFE)Approved
PFIZER INC (PFE)Approved
Protalix BioTherapeutics, Inc. (PLX)
Gaucher disease
Approved
FDA Decisions1 records
Approval1 INDICATIONS AND USAGE ELELYSO is indicated for the treatment of patients 4 years of age and older with a confirmed diagnosis of Type 1 Gaucher disease. ELELYSO is a hydrolytic lysosomal glucocerebroside-specific enzyme indicated for the treatment of patients 4 years and older with a confirmed diagnosis of Type 1 Gaucher disease ( 1 ).(PFE)FDA ↗
BLA022458Type 1 - New Molecular EntityOrphan DrugStandardIntravenousPowder

Frequently asked questions

Who is developing elelyso?

elelyso is being developed by PFIZER INC, Protalix BioTherapeutics, Inc..

What is elelyso's latest FDA decision?

The most recent tracked FDA decision for elelyso is Approval for 1 INDICATIONS AND USAGE ELELYSO is indicated for the treatment of patients 4 years of age and older with a confirmed diagnosis of Type 1 Gaucher disease. ELELYSO is a hydrolytic lysosomal glucocerebroside-specific enzyme indicated for the treatment of patients 4 years and older with a confirmed diagnosis of Type 1 Gaucher disease ( 1 )., dated May 1, 2012.